The Indian API industry stands at a pivotal moment, valued at $15-16 billion and set to climb at 5-7% CAGR in FY27 and FY28, according to CareEdge Ratings. This projection stems from proactive policies, a pivot to advanced formulations, and robust demand trends.
Domestic firms are upgrading from commodity APIs to intricate, high-potency variants to fend off price declines and elevate profitability. Enhanced penetration into regulated markets and emerging regions further amplifies this momentum.
While import dependence on China for critical inputs remains a hurdle, strides in self-sufficiency are accelerating. PLI-supported Bulk Drug Parks have delivered over 30 completed projects, with fresh capacities coming online. The agency emphasizes that these efforts, though nascent, mark a clear path forward.
An emerging pipeline of sophisticated APIs hints at value chain elevation for India. Commercial viability and scaled output, however, are 2-4 years away, promising deeper industry transformation.
CareEdge’s Pritesh Rathi outlines enduring catalysts: rising elderly demographics, healthcare advancements, expanded insurance, surging chronic conditions, competitive markets, and international forays.
With 80% of pipeline projects tied to Bulk Drug Parks, the future looks investment-heavy. High-stakes facilities in Andhra Pradesh, Himachal Pradesh, and Gujarat, budgeted at 20-40 billion rupees apiece, are designed to ramp up local production, slash imports, and optimize costs. India’s API resurgence is not just growth—it’s a strategic overhaul.